| EPB0271 | Assessment of transmitted drug resistance mutations to doravirine (MK-1439) in Argentina | E-poster | ART resistance |
| EPB0272 | Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093) | E-poster | ART resistance |
| EPB0273 | Assessment of prevalence, patterns, and risk factors of HIV drug resistance among pregnant women living with HIV in Tanzania | E-poster | ART resistance |
| EPB0274 | Subtype A1, D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Mbarara, Uganda | E-poster | ART resistance |
| EPB0275 | Interpretation of doravirine resistance by algorithm in antiretroviral-naïve people with HIV in Haiti | E-poster | ART resistance |
| EPB0276 | Pretreatment drug resistance and molecular epidemiology of HIV-1 across the Philippines | E-poster | ART resistance |
| EPB0277 | Impact of COVID-19 pandemic on HIV viral load testing in paediatric HIV clinics in the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) | E-poster | SARS-CoV-2, COVID-19 and HIV |
| EPB0278 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in persons living with HIV (PLWH): safety and immunogenicity analysis | E-poster | SARS-CoV-2, COVID-19 and HIV |
| EPB0279 | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in persons living with HIV (PLWH): Immunogenicity comparative analysis between one dose and two doses of Ad5-nCoV vaccine | E-poster | SARS-CoV-2, COVID-19 and HIV |
| EPB0280 | Assessing the Infection Prevention and Control Program during the COVID-19 era in the Health Facilities Participating in the COVIV (COVID/HIV) National Study in Mozambique, 2021-2022 | E-poster | SARS-CoV-2, COVID-19 and HIV |